Meet the Editorial Team

EDITOR-IN-CHIEF

Professor M. Peakman
King's College London, UK

Mark Peakman is Professor of Clinical Immunology at King's College London, School of Medicine. He qualified in Medicine and then conducted PhD studies on the T cell autoimmune response in Type 1 diabetes, which has become his enduring research interest. He now oversees a research group in the Department of Immunobiology at King's, with a particular focus on defining the molecular targets of autoreactive T cells in autoimmune diseases, and using antigen-specific immune modulation in an attempt to combat the loss of tolerance that underlies these syndromes.

ASSOCIATE EDITORS

Dr Danny Douek
National Institute of Allergy and Infectious Diseases/National Institutes of Health/DHHS, Bethesda, USA

Danny Douek is Chief of the Human Immunology Section at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, NIH. He received his Medical Degree from the Universities of Oxford and London, and then a PhD in Immunology from the University of London. He is a widely published author in the field of human immunology and currently the main focus of his laboratory is the pathogenesis of HIV infection.

Professor Marina Botto
Imperial College London, UK

Marina Botto is Professor of Rheumatology in the Faculty of Medicine of Imperial College London. The Faculty is one of Europe's largest medical institutions and was recently ranked 4th in world for biomedicine. Professor Botto's research focuses on complement biology and systemic autoimmunity. Over the years she has developed several animal models of complement deficiency which have helped understanding of the role of complement in SLE and renal diseases.

Dr Matthias von Herrath
La Jolla Institute for Allergy & Immunology, San Diego, USA

Matthias von Herrath and his lab are pursuing an elusive goal - a cure for type 1 diabetes. Most recently, in association with LIAI researcher Damien Bresson, this has involved the development of a combination therapy that is showing significant promise against type 1 diabetes, when caught in the early stages. Dr. von Herrath also focuses his research on controlling chronic virus infections. His novel approach, which involves blocking a key messenger molecule in the immune system, the IL-10 receptor, is showing great promise in animal studies as a possible means to treat these infections. The finding has particular relevance for hepatitis C, but may also be applicable to AIDS, cytomegalovirus and other chronic virus infections. A major theme that ties these two research areas together is the induction and characterization of antigen-specific Tregs and their testing.

Editorial Board

D. Barouch, Boston
R. Boyton, London
T. J. Braciale, Charlottesville
V. Cerundolo, Oxford
J. W. Cohen Tervaert, Maastricht
J. Coleman, London
E. Y. Denkers, Ithaca
J. Dillner, Malmo
I. Dransfield, Edinburgh
J. C. W. Edwards, London
A. Fischer, Paris
A. Godkin, Cardiff
M. Goldman, Brussels
S. T. Holgate, Southampton
R. Hohlfeld, Munich
J. D. Isaacs, Newcastle
S. Jolles, Cardiff
J.C. Jensenius, Aarhus
E. R. Kaminski, Devon
H. Longhurst, London
A. Manfredi, Milan
M. Manns, Hannover
K. Mills, Dublin
F. Nestle, London
R. Pujol-Borrell, Barcelona
I. Sabroe, Sheffield
F. P. Schena, Bari
W. Schwaeble, Leicester
S. Sriskandan, London
J. Viney, Seattle
E. de Vries, Hertogenbosch

Editorial Office

Clinical & Experimental Immunology Editorial Office
The British Society for Immunology
Vintage House
37 Albert Embankment
London
SE1 7TL
United Kingdom

Tel: 44(0)20 3031 9802
Fax: 44 (0)20 7582 2882
Email: cei@immunology.org

All manuscripts submitted to Clinical and Experimental Immunology are peer-reviewed by two independent referees and also assessed by an editor prior to publication. Referees complete a standard evaluation form, as well as providing comments for the editors and authors, ensuring that the quality of manuscripts published in the Journal is maintained to a consistently high standard. Keywords aid in the selection of referees with appropriate expertise for each manuscript submitted.

The Journal is a member of the Committee on Publication Ethics (COPE) and authors submitting manuscripts to the journal are recommended to read the Guidelines on Good Publication Practice.

The Journal is also a member of the World Association of Medical Editors.